Baseline soluble mica levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer

HIGHLIGHTS

• who: Jun Arai from the (UNIVERSITY) have published the research: Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer, in the Journal: (JOURNAL)
• what: The authors evaluated the effects of regorafenib and its metabolites M2 and M5 on MICA shedding in human CRC cell lines in_vitro, and the authors clinically investigated whether sMICA levels in plasma are associated with the efficacy of regorafenib in terms of progressionfree survival (PFS) in patients with CRC.
• how: To examine plasma sMICA levels the authors used plasma samples . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.